

1 **Title: Hematopoietic stem cells differentiate into restricted myeloid progenitors before cell division**

2 **Authors:** Tatyana Grinenko^{1*}, Anne Eugster², Lars Thielecke³, Beata Ramazs¹, Anja Krueger¹, Sevina
3 Dietz², Ingmar Glauche³, Alexander Gerbaulet⁴, Malte von Bonin^{5,6,7}, Onur Basak^{8,9}, Hans Clevers^{8,9,10},
4 Triantafyllos Chavakis^{1,2}, Ben Wielockx^{1,2*}

5
6 **Affiliations:**

7 ¹Department of Clinical Pathobiochemistry, Institute for Clinical Chemistry and Laboratory Medicine,
8 Technische Universität, Dresden, Germany.

9 ²DFG Research Centre and Cluster of Excellence for Regenerative Therapies Dresden, Technische
10 Universität Dresden, Germany,

11 ³Institute for Medical Informatics and Biometry (IMB), Technische Universität Dresden, Germany.

12 ⁴Institute for Immunology, Technische Universität, Dresden, Germany.

13 ⁵Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden,
14 Dresden, Germany.

15 ⁶German Cancer Consortium (DKTK), partner site Dresden, Germany.

16 ⁷German cancer research center (DKFZ), Heidelberg, Germany.

17 ⁸Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center
18 Utrecht, 3584 CT, Utrecht, the Netherlands.

19 ⁹Cancer Genomics Netherlands, UMC Utrecht, 3584 GC, Utrecht, the Netherlands.

20 ¹⁰Princess Máxima Centre, 3584 CT Utrecht, the Netherlands.

21

22 ***Correspondence to:** tatyana.grinenko@uniklinikum-dresden.de, ben.wielockx@tu-dresden.de

23 **Summary**

24 Hematopoietic stem cells (HSCs) continuously replenish all blood cell types through a series of
25 differentiation steps that involve the generation of lineage-committed progenitors as well as necessary
26 expansion due to repeated cell divisions. However, whether cell division in HSCs precedes differentiation
27 is unclear. To this end, we used an HSC cell tracing approach and Ki67^{RFP} knock-in mice to assess
28 simultaneously divisional history, cell cycle progression, and differentiation of adult HSCs *in vivo*. Our
29 results reveal that HSCs are able to differentiate into restricted progenitors, especially common myeloid
30 progenitors, restricted megakaryocyte-erythroid progenitors (PreMEs) and pre-megakaryocyte progenitors
31 (PreMegs), without undergoing cell division and even before entering the S phase of the cell cycle.
32 Additionally, the phenotype of the undivided but differentiated progenitors correlated with expression of
33 lineage-specific genes that manifested as functional differences between HSCs and restricted progenitors.
34 Thus, HSC fate decisions appear to be uncoupled from physical cell division. These results facilitate a
35 better understanding of the mechanisms that control fate decisions in hematopoietic cells. Our data,
36 together with separate findings from embryonic stem cells, suggest that cell division and fate choice are
37 independent processes in pluripotent and multipotent stem cells.

38

39 **Introduction**

40 A rare population of hematopoietic stem cells (HSCs) resides at the top of the hematopoietic hierarchy ¹.
41 Although most adult HSCs normally exist in a quiescent or dormant state ², some of them divide and
42 support the production of all mature blood cell types through multiple intermediate progenitor stages,
43 during steady state and in response to acute needs ³⁻⁵. This classical point of view was questioned in
44 recent studies from two groups showing that HSC populations contain stem-cell like megakaryocyte
45 progenitors, which under stress conditions such as transplantation into irradiated recipients⁶ or after acute
46 inflammation⁷, activate a megakaryocyte differentiation program. The commitment process(es) that turns

47 HSCs into mature cells are currently understood to be a sequence (or even a continuum) of decision steps
48 in which the multi-lineage potential of the cells is sequentially lost⁸⁻¹⁰. Although many of these steps
49 have been investigated in great detail, the entire picture is still repeatedly challenged^{6,8,9,11-13}. HSC
50 transition through the multipotent and restricted progenitor stages is also accompanied by intense cell
51 proliferation³. However, it is unclear whether each fate decision step is associated with one or more
52 division events, or if cell proliferation and differentiation are independent processes. Further, if
53 differentiation of HSCs does require cell division, the phase of the cell cycle that is particularly important
54 for this process is also currently unknown. The dependence of cell-fate decisions on cell cycle progression
55 was so far only shown *in vitro* for pluripotent embryonic stem cells¹⁴⁻¹⁷. However, a few reports point
56 toward a functional connection between these two processes in adult stem cells, such as neuronal stem
57 cells^{16,18}. With regard to hematopoietic stem and progenitor cells, characterization of the cell cycle itself
58 is currently ongoing¹⁹⁻²², and an understanding of how HSC fate decisions relate to cell division and cell
59 cycle progression is lacking¹⁹.

60 Therefore, we used *in vivo* cell tracing to simultaneously follow the divisional history and the initial
61 differentiation steps of HSCs. Our data reveal that HSCs are able to differentiate into restricted
62 progenitors prior to cell division, most prominently megakaryocyte-erythroid progenitors (PreME) and
63 pre-megakaryocyte progenitors (PreMeg), and that this occurs before the cells enter the S phase of the cell
64 cycle. Moreover, our data also demonstrate that the G0/G1 phases are crucial for fate decision in HSCs to
65 either differentiate or self-renew.

66

67 **Results**

68 **HSCs differentiate into myeloid progenitors *in vivo* without undergoing cell division**

69 To study the initial steps of HSC differentiation *in vivo*, we sorted Lin⁻ Kit⁺ Sca-1⁺ (LSK) CD48⁻ CD41⁻
70 CD150⁺ stem cells (Figure 1a)¹. CD41⁺ cells were excluded to avoid myeloid-²³ and megakaryocyte-

71 biased HSCs²⁴⁻²⁶. We used the CellTrace Violet dye^{27,28} to uniformly label HSCs and track cell-division
72 history after transplantation (Figure 1a). Recently, Shimoto et al have shown that numerous empty HSC
73 niches are available upon transplantation into non-conditioned recipients, which are located distant from
74 filled niches and available for HSC engraftment and proliferation. Moreover, donor HSCs give rise to all
75 blood cells without any bias²⁹. Labelled cells were transplanted into unconditioned recipients to prevent
76 irradiation-induced stress³⁰⁻³² (Figure 1a). Thirty-six hours after transplantation, 30% of the donor cells
77 had downregulated Sca-1 expression (Figure 1b), one of the principal surface markers for HSCs³³, and
78 changed their phenotype from HSCs to myeloid progenitors (MP). Importantly, the purification procedure
79 alone did not lead to down-regulation of Sca-1 (Supplementary Figure 1a). A possible contamination of
80 potential donor MPs was excluded, since transplantation of these progenitors alone did not result in any
81 detectable donor MPs 36 hours later (Supplementary Figure 1b). To further classify these phenotypically
82 restricted MPs *in vivo*, we used a previously described method of surface staining³⁴; we initially
83 confirmed its applicability after transplantation into lethally irradiated mice (Supplementary Figure 2a-b).
84 Based on surface staining at 36 h post transplantation, we subdivided donor MPs into the following
85 restricted progenitors: common myeloid progenitors (CMPs), granulocyte-macrophage progenitors
86 (GMPs), pre-megakaryocyte-erythroid progenitors (PreMEs), and pre-megakaryocyte progenitors
87 (PreMogs) (Figure 1b).

88 Next, we analyzed the proliferation history of transplanted cells based on dilution of CellTrace Violet
89 dye, whereby intensity of the dye in CD4⁺CD62L⁺ naïve T cells was used as the reference for undivided
90 cells (Supplementary Figure 1c)^{35,36}. This analysis reveals that, at 36 hours after HSC transplantation, a
91 majority of LSK cells with the long-term HSC phenotype (LSK CD48⁻ CD150⁺), short-term HSCs (ST-
92 HSC) (LSK CD48⁻ CD150⁻), multipotent progenitors (MPP2: LSK CD48⁺ CD150⁺ and MPP3/4 LSK
93 CD48⁺ CD150⁻) (Supplementary Figure 3a)¹ and 50% of the MPs remained undivided (Figure 1c).
94 Additionally, based on CD41 and CD150 expression, these MPs were predominantly CMPs, PreMEs, and
95 PreMogs (Figure 1d-e). We also performed an even more stringent gating strategy to avoid overlay

96 between non-divided and divided cells (Supplementary Figure 1d), but found no difference in the
97 frequency of restricted progenitors, as compared to the previous gating strategy (Supplementary Figure
98 1e). To exclude the possibility that HSCs differentiated into MPs without division due to the limited niche
99 space, we used the HSC-CreERT+R26^{DTA/DTA} mouse line allowing for the inducible depletion of HSCs
100 and transplanted CellTrace dye labelled wild type HSCs into them³⁷ (Supplementary Figure 1f).
101 However, we did not find any difference in the frequency of HSCs differentiated into myeloid restricted
102 progenitors 36h after transplantation, compared to controls (Supplementary Figure 1g-h). Surprisingly,
103 compared to mice not preconditioned with tamoxifen (TAM), we found that donor HSCs in TAM treated
104 mice displayed enhanced differentiation into GMPs without cell division, suggesting potentially
105 additional stress induced by TAM.

106 Interestingly, transplantation of MPP2 or MPP3/4 subsets revealed a similar phenomenon as most of the
107 MPs did not divide. Further, while MPP2 cells mostly gave rise to PreMEs and PreMeg cells, MPP3/4
108 cells differentiated into CMPs and GMPs (Supplementary Figure 3b-d). Taken together, these results
109 strongly suggest that HSCs/MPPs can give rise to restricted progenitors including CMPs, PreMEs, and
110 PreMegs based on the cell phenotype, without undergoing cell division.

111 **Phenotype of undivided differentiated progenitors correlates with expression of lineage-specific** 112 **genes**

113 To investigate the molecular differences between undivided HSCs and undivided MPs, we designed a
114 panel of primers to analyse single-cell expression levels of 70 genes including cell cycle genes and those
115 specific for HSCs, myeloid, erythroid, megakaryocyte-erythroid progenitors (MEP) and platelets
116 (Supplementary Table 1)^{8,9,11,12,33,38-41}. Essentially, single-cell expression analysis of freshly sorted HSCs,
117 CMPs, PreMEs and PreMegs showed a clear separation of the cell types whether based on all analyzed
118 genes or only on selected MEP/Platelet genes (Supplementary Figure 4a-c).

119 We then isolated undivided donor cells at 36h after transplantation of LSK CD48⁻ CD41⁻ CD150⁺ cells
120 (Figure 2a) and retrospectively categorized them on the basis of index-sorting data as HSCs (LSK CD48⁻
121 CD150⁺) or various MP populations (Supplementary Figure 5a-d). Within these populations, we
122 performed single-cell qPCR on 42 HSCs, 7 CMPs, 15 PreMEs, and 20 PreMegs, pooled and obtained
123 from two independent experiments (Figure 2b). Performing t-distributed stochastic neighbor embedding
124 (t-SNE) analysis of the qPCR data revealed separation of HSCs from PreMEs and PreMegs, based on all
125 analysed genes (Figure 2c) or the MEP/Platelet genes alone (Figure 2d, Supplementary Table 1). This
126 separation among phenotypically defined populations was also confirmed by a majority of the
127 MEP/Platelet specific genes (Figure 2e, Supplementary Tables 2, 3, 4, 5), and was similar to that
128 observed before transplantation (Supplementary Figure 4d). Thus, undivided PreME/PreMeg cells
129 obtained after transplantation express genes typically restricted to megakaryocyte-erythroid progenitors.

130 For an in-depth comparative analysis of the transplanted undivided cells (Figure 2) and non-transplanted
131 cells (Supplementary Figure 4), we performed tSNE⁴² and hierarchical cluster analysis on gene
132 expression data (Figure 3a-b). We wondered whether HSCs and PreMegs truly form distinctive subgroups
133 in terms of their gene expression profile. Therefore, we excluded the intermediate cell differentiation
134 stages (colored in green) and provided the algorithm with a number of expected clusters ($k = 2$). Figure 3b
135 illustrates that not only the visual inspection of the t-SNE visualization but also the k-means cluster
136 algorithm is able to distinguish between those two cell types. As expected, while our results reveal a close
137 association between the before- and after- transplantation HSC or PreMeg populations, HSCs and
138 PreMegs themselves form distinct clusters. Therefore, changes in the HSC phenotype before cell division
139 reflect gene expression changes associated with differentiation.

140 **HSCs differentiate into restricted progenitors before entering the S phase of the cell cycle**

141 While the cell tracing dye allowed us to follow cell division, it did not give information on cell cycle
142 progression. Therefore, to determine in which phase of the cell cycle HSCs make fate decisions, we
143 scored each cell for its likely cell cycle phase using signatures for G1, S/G2/M phases³⁹. We categorized

144 individual cells in the G₀/G₁ or the S/G₂/M phases (Figure 4a) based on the average expression of phase
145 specific genes^{39,43}. As expected, and later confirmed by expression of individual cell cycle genes (Figure
146 4b), HSCs were more quiescent, with almost one-third of the PreME/PreMeg cells still in the G₀/G₁
147 phases (Figure 4a). We also confirmed cluster separation between cells in G₀/G₁ and S/G₂/M phases by
148 performing t-SNE analysis based on all 15 measured cell cycle genes but restricted to PreME/PreMeg
149 populations (Figure 4c). Next, to determine if the expression of MEP/platelet genes is dependent on
150 progression through the S/G₂/M phases, we again used t-SNE analysis to compare PreME/PreMeg cells
151 in the G₀/G₁ and S/G₂/M phases. Remarkably, there was no separation of cells according to their cell
152 cycle status (Figure 4c), suggesting that PreME/PreMeg cells had previously upregulated differentiation
153 genes in the G₀/G₁ phases of the cell cycle. That PreME and PreMeg cells increase expression of lineage
154 specific genes independent of cell cycle phase, was further supported by comparing the mean expression
155 of MEP/Platelet genes between cells in G₀/G₁ and S/G₂/M phases (Figure 4d). Indeed, PreME and
156 PreMeg cells increase expression of the lineage specific genes independent of cell cycle phases. These
157 data imply that transplanted HSCs differentiate before entering the S phase of the cell cycle.

158 To corroborate these findings, we used the recently described Ki67^{RFP} knock-in mice⁴⁴. KI67 is a nuclear
159 protein that is absent in the G₀ phase, starts to be synthesized at the beginning of the S phase, increases
160 until mitosis, and gradually decreases thereafter in the G₁ phase of the daughter cells until re-entry into
161 the S phase⁴⁵. We first confirmed that none of the RFP⁻ cells (LSK or MP) was in the S/G₂/M phase,
162 (Supplementary Figure 6a), and that only RFP⁺ cells incorporated BrdU (Supplementary Figure 6b).
163 Using an antibody against KI67, we found that RFP⁺ expression truly reflects KI67 expression at the
164 protein level (Supplementary Figure 6c). Thus, Ki67^{RFP} knock-in mice are an appropriate tool to trace cell
165 cycle progression in hematopoietic cells.

166 To follow HSCs through cell cycle progression and differentiation, we sorted RFP⁻ HSCs residing in the
167 G₀/G₁ phases, labeled them with CellTrace Violet, and transplanted these cells into non-conditioned
168 recipients. Our results reveal that the majority of donor undivided MPs did not upregulate RFP expression

169 (Figure 4e), thus remaining in the G0/G1 phases. When taken together with the above results, these
170 findings demonstrate that HSCs do not require S phase entry to become phenotypic MPs.

171 **Functional differences between undivided HSCs and progenitors**

172 We used *in vitro* colony assays to verify functional differences between undivided phenotypic HSCs and
173 MPs due to changes in gene expression profiles. Undivided donor HSCs (LSK CD48⁻ CD150⁺) and
174 PreMegs (Lin⁻ Sca-1⁻ Kit⁺ CD150⁺ CD41⁺) were isolated at 36h after transplantation and cultured as
175 single cells in the presence of growth factors (SCF, TPO, IL-3 and EPO) ⁴⁶. Twelve days later, 89% of
176 HSCs were multipotent and gave rise to all cell types (myeloid, erythroid, and megakaryocyte), whereas
177 92% of the PreMegs differentiated into megakaryocytes alone, clearly suggesting that this population had
178 lost their multipotency (Figure 5a).

179 We further investigated the *in vivo* repopulating capacity of donor cells. For this, we sorted undivided
180 donor GFP⁺ LSK and MP cells obtained at 36h after transplantation, injected them into non-conditioned
181 recipients, and re-transplanted the same amount of cells into lethally irradiated wild type mice (Figure 5b-
182 c). Although both populations gave rise to long-lived erythroid cells, only mice transplanted with LSKs
183 displayed donor-derived GFP⁺ short-lived neutrophils and platelets at 3 weeks after transplantation
184 (Figure 5b-d). These observations imply that hematopoietic progenitor cells that down-regulate Sca-1
185 without prior cell division, as expected, exhibit a dramatic reduction in their repopulation capacity.

186

187 **Discussion**

188 In this study, we demonstrated *in vivo* that HSCs can differentiate into ST-HSCs, MPPs, and even
189 restricted myeloid progenitors, before undergoing cell division. Using a cell tracing approach and Ki67^{RFP}
190 knock-in mice, we followed HSC differentiation *in vivo* and analysed the expression of several essential
191 megakaryocyte-erythroid and myeloid specific genes, and cell-cycle genes, at the single-cell level. Our
192 findings using undivided PreMegs reveal that phenotypic and gene expression changes in undivided but

193 differentiated progenitors are accompanied by loss of multipotency and repopulation capacity after
194 transplantation. Based on restricted PreME and PreMeg progenitors as an example of differentiated cells,
195 we reveal that HSCs can initiate a specific differentiation program in the G0/G1 phases, which is before
196 the actual physical division of the cell.

197 HSCs are rare cells that give rise to numerous blood cell types through a series of intermediate
198 progenitors⁴. Multipotent and restricted progenitors intensively proliferate, making them the key
199 amplifiers of cell numbers in the hematopoietic system³. The currently accepted model of hematopoiesis
200 holds that HSCs have to divide in order to produce multipotent and lineage-restricted progenitor
201 populations^{3,47,48}. Thus, with respect to HSCs, proliferation and differentiation are currently characterized
202 as simultaneous processes, however, to date, no direct *in vivo* proof of this concept has been provided. On
203 the contrary, it is also conceivable that proliferation and differentiation exist as two independent
204 processes. A few *in vitro* studies have supported this argument and have suggested that HSC division and
205 differentiation are parallel processes. Indeed, while Mossadegh-Keller and colleagues⁴⁹ have shown that
206 the myeloid transcription factor PU.1 is induced during the first cell cycle after *in vitro* stimulation of
207 HSCs with M-CSF, Yamamoto and colleagues⁶ reported that HSCs can divide asymmetrically and give
208 rise to restricted long-term repopulating megakaryocyte progenitors even after the first division. Kent and
209 colleagues⁵⁰ have shown that HSCs down regulated a number of transcription factors responsible for self-
210 renewal division and lost long-term repopulation capacity before first division *in vitro*. Using a single cell
211 sequencing approach, Yang and colleagues demonstrated that HSCs can express megakaryocyte and
212 granulocyte specific genes during the G1 phase of the cell cycle⁵¹. However, no *in vivo* studies on the
213 possible uncoupling of HSC fate decision and cell cycle progression are currently available.

214 Indeed, the idea that cells can make fate decisions in the G1 phase of the cell cycle is not new. Pluripotent
215 stem cells (PSCs) initiate differentiation during progression through the G1 phase¹⁴ due to the presence
216 of a ‘window of opportunity’, which is dependent on epigenetic changes that occur during that phase. On
217 the other hand, PSCs maintain their pluripotent state during the S and G2 phases of the cell cycle, which

218 is regulated by the cell cycle machinery but is independent of the G1 phase¹⁷. G1 phase specific cell
219 cycle regulators such as cyclin D directly regulate the localization of differentiation transcriptional factors
220 in PSCs⁵². Our results suggest a similar mechanism, which governs cell fate decisions in embryonic
221 pluripotent and multipotent adult stem cells. Moreover, our data are also in line with another report,
222 which demonstrated that division and differentiation of B cells into plasma cells were temporally
223 separated with no significant influence on each other⁵³.

224 In summary, we show that HSC division and their differentiation are probably independent processes and
225 that HSCs make fate decisions before entering the S phase of the cell cycle. Additionally, these results
226 open new directions in determining the factors that influence HSCs fate decisions in connection with cell
227 cycle progression during normal hematopoiesis and pathologies associated with abnormal differentiation.

228

229 **References**

- 230 1 Oguro, H., Ding, L. & Morrison, S. J. SLAM family markers resolve functionally distinct
231 subpopulations of hematopoietic stem cells and multipotent progenitors. *Cell stem cell*
232 **13**, 102-116, doi:10.1016/j.stem.2013.05.014 (2013).
- 233 2 Wilson, A. *et al.* Hematopoietic stem cells reversibly switch from dormancy to self-
234 renewal during homeostasis and repair. *Cell* **135**, 1118-1129,
235 doi:10.1016/j.cell.2008.10.048 (2008).
- 236 3 Busch, K. *et al.* Fundamental properties of unperturbed haematopoiesis from stem cells in
237 vivo. *Nature* **518**, 542-546, doi:10.1038/nature14242 (2015).
- 238 4 Sawai, C. M. *et al.* Hematopoietic Stem Cells Are the Major Source of Multilineage
239 Hematopoiesis in Adult Animals. *Immunity* **45**, 597-609,
240 doi:10.1016/j.immuni.2016.08.007 (2016).

- 241 5 Nestorowa, S. *et al.* A single cell resolution map of mouse haematopoietic stem and
242 progenitor cell differentiation. *Blood*, doi:10.1182/blood-2016-05-716480 (2016).
- 243 6 Yamamoto, R. *et al.* Clonal analysis unveils self-renewing lineage-restricted progenitors
244 generated directly from hematopoietic stem cells. *Cell* **154**, 1112-1126,
245 doi:10.1016/j.cell.2013.08.007 (2013).
- 246 7 Haas, S. *et al.* Inflammation-Induced Emergency Megakaryopoiesis Driven by
247 Hematopoietic Stem Cell-like Megakaryocyte Progenitors. *Cell Stem Cell*,
248 doi:10.1016/j.stem.2015.07.007 (2015).
- 249 8 Hoppe, P. S. *et al.* Early myeloid lineage choice is not initiated by random PU.1 to
250 GATA1 protein ratios. *Nature* **535**, 299-302, doi:10.1038/nature18320 (2016).
- 251 9 Paul, F. *et al.* Transcriptional Heterogeneity and Lineage Commitment in Myeloid
252 Progenitors. *Cell* **163**, 1663-1677, doi:10.1016/j.cell.2015.11.013 (2015).
- 253 10 Velten, L. *et al.* Human haematopoietic stem cell lineage commitment is a continuous
254 process. *Nat Cell Biol* **19**, 271-281, doi:10.1038/ncb3493 (2017).
- 255 11 Cabezas-Wallscheid, N. *et al.* Identification of regulatory networks in HSCs and their
256 immediate progeny via integrated proteome, transcriptome, and DNA Methylome
257 analysis. *Cell Stem Cell* **15**, 507-522, doi:10.1016/j.stem.2014.07.005 (2014).
- 258 12 Guo, G. *et al.* Mapping cellular hierarchy by single-cell analysis of the cell surface
259 repertoire. *Cell Stem Cell* **13**, 492-505, doi:10.1016/j.stem.2013.07.017 (2013).
- 260 13 Haghverdi, L., Buettner, F. & Theis, F. J. Diffusion maps for high-dimensional single-
261 cell analysis of differentiation data. *Bioinformatics* **31**, 2989-2998,
262 doi:10.1093/bioinformatics/btv325 (2015).

- 263 14 Pauklin, S. & Vallier, L. The cell-cycle state of stem cells determines cell fate propensity.
264 *Cell* **155**, 135-147, doi:10.1016/j.cell.2013.08.031 (2013).
- 265 15 Singh, A. M. *et al.* Cell-Cycle Control of Bivalent Epigenetic Domains Regulates the
266 Exit from Pluripotency. *Stem cell reports* **5**, 323-336, doi:10.1016/j.stemcr.2015.07.005
267 (2015).
- 268 16 Dalton, S. Linking the Cell Cycle to Cell Fate Decisions. *Trends in cell biology* **25**, 592-
269 600, doi:10.1016/j.tcb.2015.07.007 (2015).
- 270 17 Gonzales, K. A. *et al.* Deterministic Restriction on Pluripotent State Dissolution by Cell-
271 Cycle Pathways. *Cell* **162**, 564-579, doi:10.1016/j.cell.2015.07.001 (2015).
- 272 18 Lange, C., Huttner, W. B. & Calegari, F. Cdk4/cyclinD1 overexpression in neural stem
273 cells shortens G1, delays neurogenesis, and promotes the generation and expansion of
274 basal progenitors. *Cell stem cell* **5**, 320-331, doi:10.1016/j.stem.2009.05.026 (2009).
- 275 19 Laurenti, E. *et al.* CDK6 levels regulate quiescence exit in human hematopoietic stem
276 cells. *Cell stem cell* **16**, 302-313, doi:10.1016/j.stem.2015.01.017 (2015).
- 277 20 Mende, N. *et al.* CCND1-CDK4-mediated cell cycle progression provides a competitive
278 advantage for human hematopoietic stem cells in vivo. *J Exp Med* **212**, 1171-1183,
279 doi:10.1084/jem.20150308 (2015).
- 280 21 Matsumoto, A. *et al.* p57 is required for quiescence and maintenance of adult
281 hematopoietic stem cells. *Cell stem cell* **9**, 262-271, doi:10.1016/j.stem.2011.06.014
282 (2011).
- 283 22 Zou, P. *et al.* p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell
284 quiescence through interactions with Hsc70. *Cell stem cell* **9**, 247-261,
285 doi:10.1016/j.stem.2011.07.003 (2011).

- 286 23 Gekas, C. & Graf, T. CD41 expression marks myeloid-biased adult hematopoietic stem
287 cells and increases with age. *Blood* **121**, 4463-4472, doi:10.1182/blood-2012-09-457929
288 (2013).
- 289 24 Miyawaki, K. *et al.* CD41 Marks the Initial Myelo-Erythroid Lineage Specification in
290 Adult Mouse Hematopoiesis: Redefinition of Murine Common Myeloid Progenitor. *Stem*
291 *Cells* **33**, 976-987, doi:DOI 10.1002/stem.1906 (2015).
- 292 25 Roch, A., Trachsel, V. & Lutolf, M. P. Brief Report: Single-Cell Analysis Reveals Cell
293 Division-Independent Emergence of Megakaryocytes From Phenotypic Hematopoietic
294 Stem Cells. *Stem Cells* **33**, 3152-3157, doi:10.1002/stem.2106 (2015).
- 295 26 Bernitz, J. M., Kim, H. S., MacArthur, B., Sieburg, H. & Moore, K. Hematopoietic Stem
296 Cells Count and Remember Self-Renewal Divisions. *Cell* **167**, 1296-1309 e1210,
297 doi:10.1016/j.cell.2016.10.022 (2016).
- 298 27 Pina, C. *et al.* Inferring rules of lineage commitment in haematopoiesis. *Nat Cell Biol* **14**,
299 287-294, doi:10.1038/ncb2442 (2012).
- 300 28 Quah, B. J. C. & Parish, C. R. New and improved methods for measuring lymphocyte
301 proliferation in vitro and in vivo using CFSE-like fluorescent dyes. *J Immunol Methods*
302 **379**, 1-14, doi:10.1016/j.jim.2012.02.012 (2012).
- 303 29 Shimoto, M., Sugiyama, T. & Nagasawa, T. Numerous niches for hematopoietic stem
304 cells remain empty during homeostasis. *Blood* **129**, 2124-2131, doi:10.1182/blood-2016-
305 09-740563 (2017).
- 306 30 Cao, X. *et al.* Irradiation induces bone injury by damaging bone marrow
307 microenvironment for stem cells. *Proc Natl Acad Sci U S A* **108**, 1609-1614,
308 doi:10.1073/pnas.1015350108 (2011).

- 309 31 Abbuehl, J. P., Tatarova, Z., Held, W. & Huelsken, J. Long-Term Engraftment of
310 Primary Bone Marrow Stromal Cells Repairs Niche Damage and Improves
311 Hematopoietic Stem Cell Transplantation. *Cell stem cell* **21**, 241-255 e246,
312 doi:10.1016/j.stem.2017.07.004 (2017).
- 313 32 Schaeue, D., Kachikwu, E. L. & McBride, W. H. Cytokines in radiobiological responses: a
314 review. *Radiat Res* **178**, 505-523, doi:10.1667/RR3031.1 (2012).
- 315 33 Wilson, N. K. *et al.* Combined Single-Cell Functional and Gene Expression Analysis
316 Resolves Heterogeneity within Stem Cell Populations. *Cell Stem Cell* **16**, 712-724,
317 doi:10.1016/j.stem.2015.04.004 (2015).
- 318 34 Pronk, C. J. *et al.* Elucidation of the phenotypic, functional, and molecular topography of
319 a myeloerythroid progenitor cell hierarchy. *Cell Stem Cell* **1**, 428-442,
320 doi:10.1016/j.stem.2007.07.005 (2007).
- 321 35 Takizawa, H., Regoes, R. R., Boddupalli, C. S., Bonhoeffer, S. & Manz, M. G. Dynamic
322 variation in cycling of hematopoietic stem cells in steady state and inflammation. *The*
323 *Journal of experimental medicine* **208**, 273-284 (2010).
- 324 36 Pietras, E. M. *et al.* Chronic interleukin-1 exposure drives haematopoietic stem cells
325 towards precocious myeloid differentiation at the expense of self-renewal. *Nat Cell Biol*
326 **18**, 607-618, doi:10.1038/ncb3346 (2016).
- 327 37 Schoedel, K. B. *et al.* The bulk of the hematopoietic stem cell population is dispensable
328 for murine steady-state and stress hematopoiesis. *Blood* **128**, 2285-2296,
329 doi:10.1182/blood-2016-03-706010 (2016).
- 330 38 Gottgens, B. Regulatory network control of blood stem cells. *Blood* **125**, 2614-2620,
331 doi:10.1182/blood-2014-08-570226 (2015).

- 332 39 Kowalczyk, M. S. *et al.* Single-cell RNA-seq reveals changes in cell cycle and
333 differentiation programs upon aging of hematopoietic stem cells. *Genome research* **25**,
334 1860-1872, doi:10.1101/gr.192237.115 (2015).
- 335 40 Klimmeck, D. *et al.* Transcriptome-wide profiling and posttranscriptional analysis of
336 hematopoietic stem/progenitor cell differentiation toward myeloid commitment. *Stem cell*
337 *reports* **3**, 858-875, doi:10.1016/j.stemcr.2014.08.012 (2014).
- 338 41 Moignard, V. *et al.* Characterization of transcriptional networks in blood stem and
339 progenitor cells using high-throughput single-cell gene expression analysis. *Nat Cell Biol*
340 **15**, 363-372, doi:10.1038/ncb2709 (2013).
- 341 42 van der Maaten, L. & Hinton, G. Visualizing Data using t-SNE. *Journal of Machine*
342 *Learning Research* **9**, 2579-2605 (2008).
- 343 43 Whitfield, M. L. *et al.* Identification of genes periodically expressed in the human cell
344 cycle and their expression in tumors. *Mol Biol Cell* **13**, 1977-2000, doi:10.1091/mbc.02-
345 02-0030. (2002).
- 346 44 Basak, O. *et al.* Mapping early fate determination in Lgr5+ crypt stem cells using a novel
347 Ki67-RFP allele. *The EMBO journal* **33**, 2057-2068, doi:10.15252/embj.201488017
348 (2014).
- 349 45 Scholzen, T. & Gerdes, J. The Ki-67 protein: from the known and the unknown. *Journal*
350 *of cellular physiology* **182**, 311-322, doi:10.1002/(SICI)1097-
351 4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 (2000).
- 352 46 Grinenko, T. *et al.* Clonal expansion capacity defines two consecutive developmental
353 stages of long-term hematopoietic stem cells. *J Exp Med* **211**, 209-215,
354 doi:10.1084/jem.20131115 (2014).

- 355 47 Eaves, C. J. Hematopoietic stem cells: concepts, definitions, and the new reality. *Blood*
356 **125**, 2605-2613, doi:10.1182/blood-2014-12-570200 (2015).
- 357 48 Sun, J. *et al.* Clonal dynamics of native haematopoiesis. *Nature* **514**, 322-327,
358 doi:10.1038/nature13824 (2014).
- 359 49 Mossadegh-Keller, N. *et al.* M-CSF instructs myeloid lineage fate in single
360 haematopoietic stem cells. *Nature* **497**, 239-243, doi:10.1038/nature12026 (2013).
- 361 50 Kent, D. G., Dykstra, B. J., Cheyne, J., Ma, E. & Eaves, C. J. Steel factor coordinately
362 regulates the molecular signature and biologic function of hematopoietic stem cells.
363 *Blood* **112**, 560-567, doi:10.1182/blood-2007-10-117820 (2008).
- 364 51 Yang, J. *et al.* Single cell transcriptomics reveals unanticipated features of early
365 hematopoietic precursors. *Nucleic acids research* **45**, 1281-1296,
366 doi:10.1093/nar/gkw1214 (2017).
- 367 52 Singh, A. M. *et al.* Signaling network crosstalk in human pluripotent cells: a Smad2/3-
368 regulated switch that controls the balance between self-renewal and differentiation. *Cell*
369 *stem cell* **10**, 312-326, doi:10.1016/j.stem.2012.01.014 (2012).
- 370 53 Duffy, K. R. *et al.* Activation-induced B cell fates are selected by intracellular stochastic
371 competition. *Science* **335**, 338-341, doi:10.1126/science.1213230 (2012).
- 372 54 Bonifacio, E. *et al.* Effects of high-dose oral insulin on immune responses in children at
373 high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. *JAMA* **313**, 1541-
374 1549, doi:10.1001/jama.2015.2928 (2015).
- 375 55 Fuchs, Y. F. *et al.* CD8+ T cells specific for the islet autoantigen IGRP are restricted in
376 their T cell receptor chain usage. *Sci Rep* **7**, 44661, doi:10.1038/srep44661 (2017).

377 56 McDavid, A. *et al.* Modeling bi-modality improves characterization of cell cycle on gene
378 expression in single cells. *PLoS Comput Biol* **10**, e1003696,
379 doi:10.1371/journal.pcbi.1003696 (2014).

380

381 **Acknowledgements**

382 TG received support from the Fritz Thyssen foundation (10.14.2.153). BW was supported by the
383 Heisenberg program (Deutsche Forschungsgemeinschaft – DFG, Germany; WI3291/ 5-1). This work was
384 supported by grants from the DFG (SFB655 “Cells into Tissues” to TC and GR4857/1-1 to TG), a CRTD
385 seed grant to TG and BW and a European Research Council grant (683145) to TC. The work of LT and
386 IG was supported by the German Federal Ministry of Research and Education, Grant number 031A315
387 “*MessAge*”. We would like to thank Dr. Vasuprada Iyengar for critically reading the manuscript.

388

389 **Author Contributions**

390 Conceptualization, T.G. and B.W.; investigation, A.K., S.D., and T.G.; methodology, T.G., A.E., L.T.,
391 B.R., M.B., A.G. and I.G.; resources, T.G., B.W., O.B. and H.C.; writing original draft, T.G. and B.W.;
392 Writing, review and editing, T.G., B.W., I.G., L.T. T.C. and A.E.; funding acquisition T.G., B.W., L.T.,
393 T.C. and I.G.; Supervision, T.G., B.W. and T.C.

394 We do not have any competing financial interests.

395 **Materials and Methods**

396 **Mice.** C57BL/6 (B6), B6.SJL-PtprcaPep3b/BoyJ (B6.SJL), HSC-CreERT/R-DTA and Ubc:GFP mice
397 were purchased from the Jackson Laboratory. Ki67^{RFP} knock-in mice have been described before ⁴⁴. All
398 mice were bred and maintained under specific pathogen-free conditions in the animal facility at the
399 Medical Theoretical Center of the University of Technology, Dresden. Experiments were performed in
400 accordance with the German animal welfare legislation and were approved by local authorities.

401 **Cre-activation.** One week before the start of TAM administration, mice were kept on low phytoestrogen
402 standard diet (LASvendi, Solingen, Germany). 30 mg tamoxifen tablets (Ratiopharm, Ulm, Germany)
403 were dissolved overnight in lipid emulsion (SMOFlipid, Fresenius Kabi, Bad Homburg, Germany). 20
404 mg/ml tamoxifen solution was applied two times (72h apart) by oral gavage at a dose of 0.2mg / g body
405 weight to animals at the age of 8 – 14 weeks.

406 **Transplantation.** Bone marrow was isolated from mouse tibia, femora, pelvis, and vertebrae, crushed,
407 and filtered through a 70- μ m cell strainer. Cells were lysed in ACK Lysis Buffer (Life technologies at
408 A10492-01), and lineage depleted using biotinylated antibodies (anti-mouse CD3 (2C11; 17A2), CD11b
409 (M1/70), CD19 (1D3), CD45R (RA3-6B2), Gr-1 (RB6-8C5), Nk1.1 (PK136)) and anti-biotin micro-
410 beads using magnetic cell separation (Miltenyi Biotec Germany Cat. 130-090-485). Cells were then
411 stained with antibodies and CellTrace Violet dye (Molecular Probes Cat. C34557) according to
412 manufacturer's instructions. Cells were sorted on a FACS Aria II or III (BD Bioscience). 3600 HSCs
413 (Lin⁻ Sca-1⁺ Kit⁺ (LSK) CD48⁻ CD41⁻ CD150⁺), 5000 MPP2 (LSK CD48⁺ CD150⁺), or 10000 MPP3/4
414 (Lin⁻ LSK CD48⁺ CD150⁻) cells were transplanted via intravenous injection into non-conditioned
415 C57BL/6 mice. CD4⁺CD62L⁺ naïve T cells (10^6), labeled with CellTrace Violet, were transplanted as
416 controls for 'undivided cells. Lymph node donor cells were analyzed 36h after transplantation along with
417 LSK cells. For transplantation of cells from Ki67^{RFP} knock-in mice, RFP⁻ cells were sorted and donor BM
418 cells were analyzed 36h after transplantation, based on CellTrace Violet staining. For competitive
419 transplantation, 20 GFP⁺ LSK cells or MPs (Lin⁻ Sca-1⁻ Kit⁺) were sorted 36h after a primary

420 transplantation of 3600 HSCs from Ubc-GFP mice into unconditioned recipient C57BL/6 mice. LSKs and
421 MPs were transplanted together with 10^5 non-fractionated BM cells from B6.SJL mice into lethally
422 irradiated (900 cGy) C57BL/6 wild-type recipients.

423 **Flow cytometry.** All analyses were done on FACS Aria II and Canto (BD Bioscience). The antibodies
424 used for staining are CD117 (2B8), Sca-1 (D7), Ter119 (Ter119), CD41 (MWRReg30), CD48 (HM48-1),
425 CD105 (MJ7/18), CD16/32 (93), CD11b (M1/70), Gr-1 (RB6-8C5), all from eBioscience, CD150 (TC15-
426 12F1; BioLegend).

427 **Single-cell index sorting.** Isolated cells were single-cell sorted into 8-well strips containing $5\mu\text{l}$ of PBS.
428 To record marker levels of each cell, the FACS Diva-7 “index sorting” function was activated during cell
429 sorting. Using index sorting, single cells were sorted from the entire $\text{Lin}^- \text{Kit}^+$ CellTrace Violet⁺ space,
430 and the intensities of the Cell Trace Violet, Kit, Sca-1, CD41, CD48, CD150, CD105, and CD16/32
431 FACS markers recorded and linked to each cell’s position.

432 **Cytospins.** Cells were spun onto object slides at 500 RPM, dried and stained with May-Grunwald and
433 Gimza solution (Sigma Aldrich).

434 **In vitro culture.** Single cells were sorted and cultured in 96 well plates in StemSpan SFEM medium
435 (STEMCELL Technologies, Cat. 09600) supplemented with 20 ng/ml rmSCF (Peprotech, 250-03), 20
436 ng/ml rmTpo (eBioscience, 34-8686-63), 20 ng/ml rmIl3 (Peprotech, 213-13), and 5 U/ml rhEpo (Roche),
437 and cultivated for 12 days at 37°C with 5% CO_2 .

438 **Cell cycle analyses.** For intracellular staining, cells were fixed and permeabilized using fixation and
439 permeabilization buffers from eBioscience. To distinguish between the G0 and G1 phase, cells were
440 stained for intracellular Ki-67 FITC (eBiosciences, clone SolA15). DAPI (4, 6 diamidino-2-phenylindole;
441 Molecular Probes) was used to measure DNA content and separate the cells in S/G2/M phases from those
442 in the G0 and G1 phase. For the BrdU incorporation assay, $10\mu\text{M}$ BrdU (Sigma-Aldrich) was added to the
443 culture for 3.5 h and BrdU incorporation analyses performed as described previously⁴⁶ using anti-BrdU-
444 FITC ab (eBioscience, clone BU20a).

445 **Clustering based analysis of cell cycle state.** Cell cycle genes were classified based on single cell deep
446 sequencing data ³⁹ or defined previously in synchronized HeLa cells ⁴³ (G1 phase genes: Ccne1, Cdk2,
447 Cdkn1a, Cdkn1c, S/G2/M phase genes: Cdkn2d, E2f4, Cdk6, Cdkn2c, Ccng2, Ccnf, Mki67, Ccna2,
448 Ccnb1, Ccnb2, Cdc20). First, expression of each gene for each cell was normalized to the maximum
449 expression of the gene; second, cell cycle signature for each cell was defined as the average expression of
450 phase specific subsets of cell cycle genes. Discrimination between G1 and S/G2/M was done based on
451 the distribution of control HSCs (before transplantation) and data that around 90% of HSCs (mouse strain
452 C57Bl6) are in G0/G1 phase of the cell cycle.

453 **Single-cell qPCR.** Gene expression profiles of single cells were obtained as previously described ^{54,55} but
454 with modifications. cDNA was synthesized directly on the cells using the Quanta qScript TM cDNA
455 Supermix. Total cDNA was pre-amplified for 20 cycles (1x 95°C 5', 95°C 45'', 60°C, 1', 72°C 1.5') and
456 once at 68°C for 10' using the Multiplex PCR Kit (Qiagen, Hilden, Germany) in a final volume of 35 µl
457 in the presence of primer pairs (25nM for each primer) for all genes (listed in Table S1). Pre-amplified
458 cDNA (10 µl) was then treated with 1.2 U Exonuclease I and gene expression quantified by real time
459 PCR on the BioMark™ HD System (© Fluidigm Corporation, CA, USA) using the 96.96 Dynamic Array
460 IFC, the GE 96x96 Fast PCR+ Melt protocol, the SsoFast EvaGreen Supermix with Low ROX (BIO
461 RAD, CA, USA), and 5 µM primers, for each assay. Raw data were analyzed using the Fluidigm Real-
462 Time PCR analysis software.

463 **Bioinformatics analysis.** Pre-processing and data analysis of single-cell expression profiles were
464 conducted using KNIME 2.11.2, R Version 3.3.2 and RStudio Version 0.99.486 and version 1.0.136
465 (Boston, MA, USA) software. Where further required, pre-processing via a linear model to correct for
466 confounding sampling effects was conducted as previously described ⁵⁴. t-SNE plots were created using
467 the R package 'Rtsne'. To model the bi-modal gene expression of single cells, the Hurdle model, a semi-
468 continuous modeling framework, was applied to pre-processed data ⁵⁶. This allowed us to assess
469 differential expression profiles as a function of frequency of expression and mean positive expression

470 using a likelihood ratio test. k-means clustering for k=2 was performed on the normalized data and using
471 the R package 'stats'.

472 **Statistical analysis.** Data were expressed as mean +/- standard deviation (s.d.). Statistical analyses based
473 on unpaired Student's t test were performed using Prism 5.0 software (GraphPad). P value <0.05 were
474 considered as statistical significant.

475

476

477

478

479

480

481

482

483

484

485


486

487

488


489

490



492 **Figure 1. Differentiation and division proliferation history of HSCs after transplantation into non-**
493 **conditioned recipients.**


494 **(a)** HSCs (LSK CD48⁻ CD41⁻ CD150⁺) were labelled with CellTrace Violet dye and 3600 cells were
495 transplanted into non-conditioned wild type mice. Purity of transplanted cells was more than 99% for
496 each experiment. **(b)** Bone marrow was harvested at 36h after transplantation and recipient cells were
497 analyzed using indicated gates. **(c)** Dilution of CellTrace Violet in donor LSK and MPs, 36h after
498 transplantation. Labelled and transplanted naïve CD62L⁺CD4⁺ T cells were used as reference for
499 undivided cells. 500 donor cells were analyzed from 11 transplanted mice, representative data for one out
500 of 13 experiments **(d)** Phenotype of undivided and divided donor MPs (n=11), representative example of
501 13 independent experiments. **(e)** Frequency of restricted progenitors in undivided ('0' div.) and divided (1
502 div.) donor MPs, pooled data from 13 independent experiments. Unpaired Student t-test, data are means
503 +/- S.D., P***=0.0002, P*=0.02.



504

505 **Figure 2. Single cell expression analysis in undivided donor HSCs and MPs.**

506 **(a)** Experimental design. LSK CD48⁻ CD41⁻ CD150⁺ cells were transplanted into non-irradiated
507 recipients, and single, undivided donor Lin⁻ Kit⁺ cells were sorted using the index sort approach at 36h
508 after transplantation. Data from two independent experiments (n= 12 mice). Based on index sort data,
509 HSCs were defined as LSK CD48⁻ CD150⁺; CMPs as Lin⁻ Kit⁺ Sca-1⁻ CD16/32⁻ CD41⁻ CD150⁻ CD105⁻;
510 PreME as Lin⁻ Kit⁺ Sca-1⁻ CD16/32⁻ CD41⁻ CD150⁺ CD105⁻; and PreMeg as Lin⁻ Kit⁺ Sca-1⁻ CD16/32⁻
511 CD41⁺ CD150⁺ CD105⁻. All sorted 42 HSC, 7 CMP, 15 PreME and 20 PreMeg cells were analyzed. **(b)**
512 Heat map showing gene expression analysis. Each row corresponds to a specific gene, each column
513 corresponds to a specific and individual donor cell, and colors represent expression levels of individual
514 genes (dCt). **(c)** t-SNE plot for all analyzed genes and cells, axes have arbitrary units. **(d)** t-SNE plot for
515 MEP/Platelet genes for all cells, axes have arbitrary units. **(e)** Violin density plots for the most differently
516 expressed MEP/Platelet genes. Y-axis represents gene expression. The horizontal width of the plot shows
517 the density of the data along the Y-axis. Statistical significance was determined using the Hurdle model.
518 *(p<0.05), **(p<0.01), ***(p<0.0001), ns (not significant). Data from 2 independent experiments, n=12.
519 Exact P value in supplemental Tables S2-3.




520

521 **Figure 3. Comparison of gene expression between cells before transplantation and undivided cells**
522 **after transplantation.**

523 (a) t-SNE plot for all analyzed genes (top panel) and MEP/Platelet genes (bottom panel) for all cells

524 before transplantation and undivided donor cells at 36h after transplantation. Axes display arbitrary units.


525 **(b)** t-SNE visualization for all cells before transplantation and all undivided cells after transplantation
526 (36h). The color coding depicts the results of a reproducible k-means clustering (k=2) on all cells before
527 and after transplantation based on MEP/Platelet genes.



528

529 **Figure 4. Cell cycle distribution of undivided donor HSCs, CMPs, PreMEs, and PreMegs.**

530 **(a)** Prediction of cell cycle phases for all undivided donor cells 36h after transplantation. Shown is the
531 average expression of G1 genes (x-axis) and S/G2/M genes (y-axes) **(b)** Violin density plots for the most
532 differently expressed cell cycle genes. Y-axis represents gene expression. The horizontal width of the plot
533 shows the density of the data along the Y-axis. Statistical significance was determined using the Hurdle
534 model. *($p < 0.05$), **($p < 0.01$), ***($p < 0.0001$). Exact P value in supplemental Tables 2-3. **(c)** t-SNE plots
535 for PreME/ PreMeg cells based on cell cycle genes and MEP/Platelet genes. **(d)** Mean expression of
536 MEP/Platelet genes was calculated for HSCs, PreMEs and PreMegs in G0/G1 and S/G2/M phases and is
537 depicted as fold-increase relative to mean expression in HSCs in the G0/G1 phases. **(e)** RFP expression in
538 undivided donor MPs at 36h after transplantation of RFP⁺ HSCs from Ki67^{RFP} knock-in mice. Recipient
539 MPs were used as negative controls for RFP expression. (Representative example, n=5, from 2
540 independent experiments).



541

542 **Figure 5. Functional analysis of undivided donor HSCs and MPs.**

543 **(a)** Individual undivided donor HSCs (LSK CD48⁻ CD150⁺) and PreMeg (Lin⁻ Sca-1⁻ Kit⁺ CD41⁺
544 CD150⁺ CD16/32⁻) cells were sorted 36h after transplantation and cultivated in liquid culture media
545 supplemented with mSCF, mTPO, mIl3 and hEpo. Cell composition was analyzed after 12 days using
546 May-Grunwald-Giemsa staining. Colonies (n=31) for HSCs and (n=25) PreMegs, 3 independent
547 experiments, 15 mice. 82% HSCs generated colonies (more than 20 cells) and 79% PreMegs generated
548 more than 3 megakaryocytes. **(b)** Reconstitution experiment using Ubc-GFP mice. **(c)** Peripheral blood
549 analysis at 3 weeks after secondary transplantation into lethally irradiated recipients. Donor cell
550 contribution to peripheral blood neutrophils (PMNs) CD11b⁺ Gr1⁺, platelets Ter119⁻ CD41⁺, and
551 erythrocytes Ter119⁺. Representative plots and pictures from 2 independent experiments (n=5). We
552 checked the mice every 3-4 weeks for a period of 16 weeks after transplantation, but did not find any
553 repopulation from MPs. **(d)** Quantification of peripheral blood analysis from 2 independent experiments,
554 n=5. Statistical significance was determined using unpaired Student's t-test *(p<0.05). Data are means +/-
555 S.D.
556